�깉濡�寃� 媛쒕컻�맂 諛붿씠援ъ븘�굹�씠�뱶 �솕�빀臾쇱뿉 �쓽�븳 援먯쥌 醫낆뼇援� �뼲�젣 �슚怨� by 理쒖��젙
  
저작자표시-비영리-변경금지 2.0 대한민국 
이용자는 아래의 조건을 따르는 경우에 한하여 자유롭게 
l 이 저작물을 복제, 배포, 전송, 전시, 공연 및 방송할 수 있습니다.  
다음과 같은 조건을 따라야 합니다: 
l 귀하는, 이 저작물의 재이용이나 배포의 경우, 이 저작물에 적용된 이용허락조건
을 명확하게 나타내어야 합니다.  
l 저작권자로부터 별도의 허가를 받으면 이러한 조건들은 적용되지 않습니다.  
저작권법에 따른 이용자의 권리는 위의 내용에 의하여 영향을 받지 않습니다. 
이것은 이용허락규약(Legal Code)을 이해하기 쉽게 요약한 것입니다.  
Disclaimer  
  
  
저작자표시. 귀하는 원저작자를 표시하여야 합니다. 
비영리. 귀하는 이 저작물을 영리 목적으로 이용할 수 없습니다. 
변경금지. 귀하는 이 저작물을 개작, 변형 또는 가공할 수 없습니다. 
Inhibiting stemness and invasion property 
of glioblastoma tumorsphere  
by a newly designed biguanide 
       
 
 
 
 
 
 
 
 
 
 
 
 
 
Junjeong Choi  
Department of Medical Science 
The Graduate School, Yonsei University 
Inhibiting stemness and invasion property 
of glioblastoma tumorsphere  
by a newly designed biguanide 
 
Directed by Professor Se Hoon Kim 
 
 
 
The Doctoral Dissertation 
submitted to the Department of Medical Science, 
the Graduate School of Yonsei University 
in partial fulfillment of the requirements  
for the degree of Doctor of Philosophy 
 
 
 
 
 
 
Junjeong Choi 
 
 
 
June 2015 
This certifies that the Doctoral Dissertation 
of Junjeong Choi approved. 
 
 
 
---------------------------------------------------------- 
Thesis Supervisor: Se-Hoon Kim 
 
---------------------------------------------------------- 
Thesis Committee Member#1: Jong Hee Chang 
 
---------------------------------------------------------- 
Thesis Committee Member#2: Seok-Gu Kang 
 
---------------------------------------------------------- 
Thesis Committee Member#3: Yun-Han Lee 
 
---------------------------------------------------------- 
Thesis Committee Member#4: Hyoung-Pyo Kim 
 
The Graduate School  
Yonsei University 
 
 
 
 
June 2015 
ACKNOWLEDGEMENTS 
First of all, I would like to thank my thesis advisor, Dr. Se Hoon 
Kim, for his guidance and support since I joined the society of 
Pathology back in 2006. Truly, he has been the best mentor in many 
aspects of my life. I deeply appreciate his patience and enormous 
encouragement during the course of the study. I have learned a great 
deal and have grown a lot through all the experiences with him. I 
also thank my thesis committee members, Prof. Jong Hee Chang, 
Prof. Seok-Gu Kang, Prof. Yun-Han Lee and Prof. Hyoung-Pyo 
Kim, for their invaluable advice and thoughtful consideration.   
I also appreciate the people in the Department of Pathology and 
Kang’s lab, for their help during the thesis work. With their help 
and encouragement, I could take a firm stand during the time.  
I would like to thank my family and friends, for their unconditional 
love and support. I specially thank Wonseon, for all those time we 
have spent together and Kyung Won, Haeryoung, Sangkyum, for 
the trust they have shown me all those time. And finally, I cannot 
thank “you” enough.  
 
 
 
Junjeong Choi 
TABLE OF CONTENTS  
ABSTRACT··············································································1 
I. INTRODUCTION···································································3 
II. MATERIAL AND METHODS ·················································10 
1. Cells ·········································································· 10 
2. Lentiviral vector transduction and expression ·························10 
3. Cell viability assay  ·······················································11 
4. Western blotting ·····························································11 
5. Neurosphere formation assay··············································12 
6. Three dimensional invasion assay ········································12 
7. Uptake of 18F-fluorodeoxyglucose(FDG) ····························14 
8. Gene expression microarray and gene ontology analysis·········15 
9. Orthotopic xenograft animal model······································16 
10. Statistical analysis···························································17 
III. RESULTS·········································································· 18 
1. The chemical structure of HL156A ······································18 
2. The effect of HL156A, TMZ and combination treatment on cell     
viability·······································································19 
3. Effect of HL156A, TMZ and combination treatment on AMPK and 
mTOR pathway of GSC11 and X01 tumorspheres ···················19 
4. The effect of HL156A, TMZ and combination treatment on the 
stemness of GSC11 and X01 tumorspheres ···························20 
5. The effect of HL156A, TMZ and combination treatment on 
neuro-glial differentiation of GSC11 and X01 tumorspheres······21 
6. The effect of HL156A, TMZ and combination treatment on the 
invasive property of GSC11 tumorspheres ····························21 
7. Assessment of cellular metabolism by analyzing 18F-FDG 
uptake·········································································24 
8. Gene ontology analysis of gene expression microarray data        
······························································25 
9. The effect of HL156A on the xenografted tumor growth ············26 
 
IV. DISCUSSION·······································································35 
V. CONCLUSION·····································································41 
REFERENCE··········································································· 43 
ABSTRACT (IN KOREAN) ·························································49 
LIST OF FIGURES 
 
Figure 1. The structure of HL156A (N-(N-(4- (trifluor omethoxy) 
phenyl) carbamimidoyl) pyrrolidine -1- carboximi 
damide acetate) and metformin···························18 
Figure 2. The effect of HL156A, TMZ and combination treatment 
on stem cell viability········································ 20 
Figure 3. The effect of HL156A, TMZ and combination treatment 
on stemness of glioblastoma tumorspheres···············23 
Figure 4. The effect of HL156A, TMZ and combination treatment 
on neuro-glial differentiation of glioblastoma 
tumorspheres ·················································24 
Figure 5. The effect of HL156A, TMZ and combination treatment       
o n  t h e  i n v a s i v e  p r o p e r t y  o f  g l i o b l a s t o m a 
tumorspheres··················································27 
Figure 6. F18-FDG uptake was markedly decreased in HL156A, 
TMZ and combination treatment·····························29 
Figure 7. High throughput gene expression microarray·············30  
 
 
 
LIST OF TABLES 
 
Table 1. Results of gene ontology analysis····························31  
1 
 
 
ABSTRACT 
Inhibiting stemness and invasion property of glioblastoma tumorsphere  
by a newly designed biguanide 
Junjeong Choi 
Department of Medical Science 
The Graduate School, Yonsei University 
(Directed by Professor Se Hoon Kim) 
 
 Glioblastoma (GBM) is a lethal disease with limited survival in spite 
of recent therapeutic progress and a new strategy against the disease is being 
required.  Recently, the effect of biguanide derived agents are being suggested 
as new groups of target in the treatment of malignant tumors and their effect 
against the tumorsphere (TS) were reported.  In this study, I assessed effects of 
a newly developed biguanide, HL156A, on the properties of glioblastoma 
tumorsphere (GBM-TS) and survival of orthotopic xenograft animals, to assess 
the feasibility of this agent, alone or combined with conventional therapeutic 
agent temozolomide (TMZ), in the treatment of GBM. HL156A, alone and 
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combined with TMZ, exhibited an inhibitory effect on the stemness of GBM-
TS, proven by the neurosphere formation assay and the assessment of stemness 
marker expression, without affecting viability of cells.  The invasive property 
of GBM-TS were inhibited most significantly by the combination treatment, 
compared with the control and HL156A or TMZ alone-treated groups in 3-
dimentional collagen matrix invasion assay.  The combination treatment 
repressed epithelial-mesenchymal transition (EMT) related gene expression.  
Gene ontology class comparison of TMZ and combination treatment group 
revealed altered expression of gene sets involving cellular adhesion and 
migration. The combined treatment of HL156A and TMZ showed survival 
benefits in the orthotopic xenograft mouse model. Targeting of GBM-TSs by 
the combination of HL156A and TMZ, through the inhibition of stemness and 
invasion properties of GBM- TS, can be a novel candidate for the treatment of 
GBM. 
 
-------------------------------------------------------------------------------------------------------  
Key words: biguanide, glioblastoma, HL156A, invasion, stemness, 
tumorsphere   
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Inhibiting stemness and invasion property of glioblastoma tumorsphere  
by a newly designed biguanide 
Junjeong Choi 
 
Department of Medical Science 
The Graduate School, Yonsei University 
 
(Directed by Professor Se Hoon Kim) 
 
I. INTRODUCTION 
1. Glioblastoma 
Glioblastoma (GBM) is the most fatal brain tumor, showing a very 
limited survival rate in spite of best treatment. Standard first line therapy is a 
surgery followed by concurrent temozolomide (TMZ) treatment and radiation. 
According to National Comprehensive Cancer Network (NCCN) guidelines of 
central nervous system cancer, only a third of patients survive for one year and 
less than 5% lives beyond 5 years.1 Temozolomide, an alkylating (methylating) 
agent, is now the standard of care in conjunction with postoperative radiation 
therapy (RT) for younger, good performance patients with GBM.1 Stupp et al 
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conducted a phase III, randomized study that assessed the drug in 573 GBM 
patients’ age ≤70 years with a WHO PS(performance status) of 2 or less. In this 
study, the chemoradiation group resulted in a statistically improved median 
survival (14.6 vs. 12.1 months) and 2-year survival rate (26.5% vs. 10.4%) 
compared with radiation alone.2 However, the patients ultimately succumb to 
death by the relapse of the disease. 
 Understanding of molecular genetics of GBM was accelerated by the 
finding that O6-methylguanine–DNA methyltransferase (MGMT) methylation 
could be a good predictor of tumor treatment by alkylating agent, TMZ.3 The 
monumental project, the cancer genome atlas (TCGA) study even more 
provided tremendous information of genome of GBM. Using high-throughput 
studies and bioinformatics analysis, it was shown that there exist four molecular 
subtypes of the tumor: classical, mesenchymal, proneuronal and neural types. 
In addition, they showed response to the aggressive therapy differed by subtype, 
with the greatest benefit in the classical subtype and no benefit in the proneural 
subtype.4  Further study revealed the existence of a glioma-CpG island 
methylator phenotype (G-CIMP) with characteristic clinical phenotypes  and 
survival advantage of the proneural subtype is conferred by the G-CIMP 
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phenotype, and MGMT DNA methylation may be a predictive biomarker for 
treatment response only in classical subtype GBM.5-6 
2. Cancer stem cell hypothesis 
Growing body of evidence that supports the idea that cancers are 
initiated and maintained by a subpopulation of cells are being reported. Ever 
since the compelling evidence proving existence of cancer stem cells (CSCs) in 
acute myeloid leukemia by Bonnet and Dick in 1997, CSCs have been 
identified in multiple human malignancies including breast, brain, colon, ovary 
and pancreas.7-12 The ideas that the organization of cell lineage in tumors is 
hierarchical and only a subset of cells is responsible for tumor progression are 
main subjects of this theory. Adult stem cells and their progenitors are being 
recognized as one of sources of tumor initiating cells. Regardless of the origin, 
CSC is defined by its stem cell-like properties like self-renewing capability, 
generating a hierarchy organization harboring varied downstream descent, 
proliferating extensively and initiating tumor.13 The presence of CSCs raises 
the clinical implication that a curative therapy will require complete elimination 
of this unique population in patients with an initial response to treatment, since 
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the disease may ultimately recur if even a small number of CSCs survive the 
therapy. Interestingly, accumulated evidence has established that CSC 
populations are more resistance to conventional cancer therapy than non-CSC 
population. For example, CD133 positive GBM CSCs displayed strong 
capability on tumor’s resistance to chemotherapy and radiotherapy.14,15 
Consequently, novel therapeutic systems have been developed with the purpose 
of targeting CSCs and altering the microenvironment these cell potentially 
resides. Targeting surface of markers, signaling cascades, microenvironments 
were being tried and examined.16  
Recent experimental data suggest that CSCs are responsible for GBM 
invasiveness, a most important characteristic of the tumor that renders complete 
tumor resection almost impossible. Cells enriched for the putative stem cell 
marker C133 display greater migratory and invasive potential in vitro and in 
vivo when compare with matched CD133-negative tumor cells derived human 
primary GBMs, GBM xenograft and brain tumor cell lines.14,17 Moreover, 
putative stem cell marker-positive cells were found in the leading edge of the 
tumor.18 Given that there is a notion that CSCs are functionally heterogeneous 
in terms of surface marker expression, neurosphere formation ability, and in 
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vivo tumorigenic potential, it is possible that CSCs switch from a stationary and 
proliferative phenotype to a migratory one and vice versa, ensuring the 
enlargement of the tumor core and the colonization of the neighboring normal 
brain tissue.19,20  
3. Epithelial to mesenchymal transition in glioblastoma 
Although originally identified as a process in the development, 
epithelial to mesenchymal transition (EMT) is a process that allows a 
differentiated epithelial cells, entirely settled and patterned to establish stable 
contacts with neighbor cells, to acquire a mesenchymal cell phenotype, 
characterized by loss of cell to cell interactions,21 reduced cellular adhesion,22 
increased cytoskeletal dynamic23 and changes in transcription factor,24 all of 
which ultimately lead to increased migration and invasion property. Adapting 
this unique process by cancer cells was known to be associated with the 
acquisition of a stem cell program.25 SNAI1, TWIST and Zinc-finger enhancer 
binding (ZEB) family members regulate the program and the activity of them 
has been reported to be altered in GBM. SNAI is known to be involved in the 
regulation of glioma cell proliferation and migration.19,26 The ZEB2 expression 
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level was significantly increased in glioma and the silencing of the molecule 
reduced the expression of mesenchymal cell markers.27 Mesenchymal subtype 
of GBM was identified in TCGA data set and high expression of genes 
associated with mesenchyme derived tissue is related with poor overall survival 
and treatment resistance.4 They speculated this could be considered reminiscent 
of the EMT program.4 Another speculation is that aberrant activation of EMT 
factors during tumorigenesis can trigger the mesenchymal shift in GBM.28 
4. Biguanide as a potential therapeutic agent for the treatment of GBM through 
targeting of cancer stem cells 
Since studies unveiled that the biguanide derivate, metformin (N’,N’-
dimethylbiguanide), the most widely used oral therapeutic agent to lower blood 
glucose concentration in patient with type 2 diabetes, significantly reduced 
cancer incidence and improved cancer pateints’ survival in type 2 diabetics,  
laboratory evidence of antineoplastic effect of biguanide has been accumulated 
and first generation of clinical trials on metformin in progress are 
anticipated.29,30  Direct action of biguanides on transformed cells or cells at risk 
for transformation was attributed to a consequence of homeostatic response to 
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the agent-induced energetic stress or may be attributed to energy depletion by 
the inhibition of oxidative phosphorylation (OXPHOS) which leads to the 
energy conservation state or 5' adenosine monophosphate-activated protein 
kinase(AMPK) activation within the cells, but still under investigation. 
Remarkably, Hirsch et al. have demonstrated that mass-forming, self-renewing 
tumor initiating breast cancer cells seems to exhibit an exacerbated sensitivity 
to metformin.31 This group suggest that TGF-β-induced EMT might represent 
a common molecular mechanism underlying the anti-cancer stem cells actions 
of metformin.29 However, supporting studies for this notion are still limited.  
In the present study, I assessed the effect of HL156A, alone or 
combined with conventional therapeutic agent, TMZ, on the properties of 
GBM-TS and survival of orthotopic xenografted animals, to evaluate the 
feasibility of new drug, as a potential therapeutic agent for GBM. 
  
10 
 
II. MATERIALS AND METHODS  
1. Cells 
GSC11, established at M.D. Anderson Cancer Center-Houston from 
primary gliomas removed from glioma patients and the X01 line, derived from 
a woman with GBM were used for experiment.32,33  
2. Lentiviral vector transduction and expression 
GFP stably expressed GSC11s (G-GSC11) were generated by growing 
GSC11 cells in complete medium and then applying GFP-expressing lentiviral 
supernatants. Polybrene (Sigma) was added to a final concentration of 8 μg/ml 
and incubated with cells for 18 hours. After infection, the cells were placed in 
fresh growth medium and cultured in a standard manner. Cells were treated with 
1 mg/ml puromycin (Life Technologies Korea, Seoul, Korea) to eliminate 
uninfected cells and generate stable G-GSC11. G-GSC11s were isolated for use 
in further experiments by fluorescence‑activated cell sorting (FACS). 
  
11 
 
3. Cell viability assay 
The effect of HL156A, TMZ and combined HL156A and TMZ on the 
survival of cells was determined by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl 
tetrazolium bromide (MTT) assay.  Cells were seeded in 96-well plates and 
incubated at 37°C for 24 hours and treated with HL156A, TMZ and their 
combination for 5 days. MTT reagent (10μl/well) was added, incubated at 37°C 
for 4 hours and the absorbance was measured at 490nm. Each experiment was 
repeated three times in triplicate and the results were expressed as % viable 
cells over control. 
4. Western blotting 
Total protein of 20 μg from each sample was treated with Laemmli 
sample buffer and heated at 100℃ for five minutes. Then it was loaded into 
each well and was resolved by 8% SDS-polyacrylamide gel electrophoresis 
(PAGE) and electroblotted onto nitrocellulose membranes (GE Healthcare life-
Sciences). Membranes were blocked in 5% non-fat dry milk in TBS-T, and 
incubated with antibodies for AMPK-mammalian target of rapamycin (mTOR) 
pathway related proteins, stemness markers, EMT-related markers, overnight at 
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4°C, and then probed with peroxidase-conjugated goat anti-rabbit IgG (1:2000, 
Santa Cruz Biotechnology INC., CA, USA) for 1 hour at room temperature. 
The washes were repeated and the membrane was developed with a 
chemiluminescent agent (ECL; Amersham Life Science, Inc.). Band densities 
were measured using TINA image software (Raytest, Straubenhardt, Germany). 
5. Neurosphere formation assay 
The GSC11 and X01 cells were cultured in medium consisting of 
DMEM/F-12 with 2 % 1×B27, 20 ng/ml 0.02 % bFGF, 20 ng/ml of 0.02 % EGF, 
and 1 % antibiotic–antimycotic solution (100×, Gibco, Invitrogen Korea, Seoul, 
Republic of Korea). The cells were cultured in different conditions for 3 weeks. 
Cell cultures were observed with an inverted phase-contrast microscope (I×71 
Inverted Microscope; Olympus, Tokyo, Japan) to determine morphology and 
the size of the tumor sphere. Photographs of cells were obtained with a digital 
camera (DP70 Digital Microscope Camera; Olympus), using DP Controller 
software (Olympus, Tokyo, Japan). 
6. Three dimensional invasion assay 
The G-GSC11s grown in spheroid i.e. tumorsphere (TS) were cultured 
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in collagen I matrices using polydimethylsiloxane (PDMS)-based micro-wells 
(diameter and depth of microwells: 6mm and 500μm). The microwells were 
treated with 1% poly (ethyleneimine) (Sigma-Aldrich, St. Louis, MO, USA) 
solution for 10 minutes followed by 0.1% glutaraldehyde (Sigma-Aldrich, St. 
Louis, MO, USA) for 30 mins and washed with PBS for overnight to make 
PDMS wells adherent to collagen. The 4mg/ml collagen I matrices are prepared 
from high-concentration rat tail collagen I (BD Bioscience, CA, USA) using 
the recommended manual provided by the manufacturer. Briefly, the amounts 
of 10x phosphate buffered saline (PBS), 1N NaOH, sterile dH2O and collagen 
I were mixed to create gels based on the desired final concentration. The 
solution is well mixed and kept at 4℃ before use. To encapsulate G-GSC11 
spheroid, 10ul of collagen I solution (4mg/ml) were pipetted into the micro-
well, single G-GSC11 TS is placed onto collagen I matrices from culture plate, 
and 10ul of collagen I solution (4mg/ml) was dropped onto G-GSC11 TS. The 
platform was incubated at 37℃ and 5% CO2 for 30 mins. The cell viability was 
characterized by staining G-GSC11 TS with 8μM Ethidium homodimer-1 
(Invitrogen Korea, Seoul, South Korea) for 30 mins at 37℃ before implantation 
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in collagen matrix. After full gelation, a superlayer of culture medium 
consisting of DMEM/F-12 with 2 % 1×B27, 20 ng/ml 0.02 % bFGF, 20 ng/ml 
of 0.02% EGF, and 1% antibiotic–antimycotic solution (100×, Gibco, 
Invitrogen Korea, Seoul, South Korea) is then added. To observe drug effects, 
drugs are mixed with medium considering final concentration of each drug. 
Images were taken using an inverted confocal laser scanning microscope 
(Nikon Ti-E, Tokyo, Japan) to observe dynamic morphology of G-GSC11 TSs. 
To quantitate the invasion assay, the maximal area covered by migrating edges 
of cells were used as a parameter for defining invasiveness (invaded area at 
certain time/TS area at initial time×100). Data are analyzed through image 
analysis software ImageJ (NIH, Bethesda, Maryland, USA). 
7. Uptake of 18F-fluorodeoxyglucose (FDG) 
GSC11 cells were plated on 12-well plates with 3x105 cells per well 
for 24 hrs. The medium was changed to a glucose-free DMEM medium (Gibco, 
Invitrogen Korea, Seoul, South Korea) containing approximately 0.5 uCi of 18F-
FDG, followed by incubation for 15min. The cells were washed with 
phosphate-buffered saline 3 times and 0.1 mL of lysis buffer was added to each 
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well. The lysed cells were then harvested to measure the amount of radioactivity 
by Wallac 148 Wizard 3 gamma-counter (PerkinElmer Life and. Analytical 
Science, Shelton, CT, USA). The radioactivity measured was normalized to 
protein content. 
8. Gene expression microarray and gene ontology analysis 
Total RNA was extracted from 100mg of tissue using a Qiagen 
miRNA kit according to the manufacturer’s protocol. Expression profiles of 
drug treated groups and control were obtained using Illumina HumanHT-12 v4 
Expression BeadChip (Illumina, Inc., San Diego, CA,USA) Data were log2 
transformed and normalized with quantile normalization method using BRB-
ArrayTools developed by Dr. Richard Simon and BRB-ArrayTools 
Development Team. Genes showing minimal variation across the set of arrays 
were excluded from the analysis. Genes whose expression differed by at least 
1.5 fold from the median in at least 20% of the arrays were retained. Gene set 
comparison tools provided by BRB-ArrayTools was used for Gene ontology 
analysis.  
  
16 
 
9. Orthotopic xenograft animal model 
Four-to 8-week-old male athymic nude mice (Central Lab. Animal 
Inc., Seoul, South Korea) were used for experiments. Mice were housed in 
micro-isolator cages under sterile conditions and observed for at least 1 week 
before study initiation to ensure proper health. Lighting, temperature, and 
humidity were controlled centrally. All experimental procedures were approved 
by Yonsei University College of Medicine Institutional Animal Care and Use 
Committee. Mice were anesthetized with a solution of Zoletil® (30 mg/kg; 
Virbac Korea, Seoul, South Korea) and xylazine (10 mg/kg; Bayer Korea, Seoul, 
South Korea) delivered intraperitoneally. GSC11 were implanted into the right 
frontal lobe of nude mice using a guide-screw system within the skull. Mice 
received 5×105 cells via a Hamilton syringe Dongwoo Science Co., Seoul, 
South Korea) inserted to a depth of 4.5 mm. Then, 15mg/kg of HL156A 
30mg/kg of TMZ and their combination were administrated to mice. HL156A 
was given to mice by oral administration every other day until the duration of 
the experiment and TMZ was administrated intraperitoneally, for 5 days from 
the day of tumor sphere injection. Five animals per group were injected. The 
body weight of mice was checked every other day. 
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 If the weight decreased more than 15 % compared to the original body 
weight, mice were euthanized according to protocol. When mice died, we 
carefully removed mouse brains and observed gliomagenesis after generating 
Hematoxylin-Eosin stained slides. 
10. Statistical analysis 
Data were analyzed using SPSS for Windows, Version 12.0 (SPSS Inc., 
Chicago, IL, USA) and STATA Statistical Software Release 13(StataCorp LP., 
College Station, TX, USA).  Student T-test was used for comparison of mean 
of viability and FDG uptake of agent treated cells. Kaplan-Meier survival 
curves and log-rank statistics were employed for survival analysis. Results were 
considered statistically significant when P<0.05.  
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III. RESULTS 
1. The chemical structure of HL156A  
The chemical structure of HL156A (N-(N-(4-(trifluoromethoxy) 
phenyl) carbamimidoyl) pyrrolidine-1-carboximidamide acetate) is depicted in 
Figure 1. It is a derivative of biguanide with high bioavailability. In contrast to 
metformin having limited brain-blood barrier permeability and low 
bioavailability, it enters the cell independent of OCT1 transporter and highly 
penetrates to brain.  
 
Figure 1. The structure of HL156A (N-(N-(4-(trifluoromethoxy) phenyl) 
carbamimidoyl) pyrrolidine-1-carboximidamide acetate, left) and 
metformin (right). The compound contains a central part of metoformin, the 
biguanide, in its composition.  
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2. The effect of HL156A, TMZ and combination treatment on cell viability 
Using GBM cancer stem cell line X01 and GSC11, I examined cell 
viability on the treatment of the HL156A, TMZ and combined HL156A and 
TMZ by MTT assay. The sublethal dose treatment of the agents showed 
minimal effect on the cells. (Figure 2A). I used sublethal dose of each drug as 
we pursued specific cellular phenomenon without killing cells. I adopted 15μM 
of HL156A and 500μM of TMZ for further experiments (Figure 2B).  
3. Effect of HL156A, TMZ and combination treatment on AMPK and mTOR 
pathway of GSC11 and X01 TSs 
Generally, it is known that biguanide works as AMPK agonist and 
consequently, mTOR inhibition is followed. However, this was not the case in 
GBM-TS. mTOR inhibition by AMPK activation was not observed in GSC11 
and X01 cells.  
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Figure 2. The effect of HL156A, TMZ and combination treatment on stem 
cell viability. (A) The treatment showed minimal effect on the cell viability. (B) 
The effect of drugs on AMPK and mTOR pathway. Even though it is known 
that biguanide works as AMPK agonist and consequent mTOR inhibition is 
followed, this was not observed in GSC11 and X01 TSs (*: statistically 
significant, ns : statistically not significant, TMZ: temozolomide, TS: 
tumorsphere). 
 4. The effect of HL156A, TMZ and combination treatment on the stemness of 
TSs 
HL156A seems to decrease stemness of GSC11 and X01, proven by 
neurosphere formation assay (Figure 3A and 3B) and western blotting of 
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stemness markers such as nestin, CD133, Sox-2, Notch 1, Notch 2 and Oct3/4   
(Figure 3C). The number of neurosphere was markedly decreased on the 
treatment of HL156A and this inhibitory effect was most prominent in the 
combination treatment. Decreased expression of  CD133, OCT 3/ 4, Sox-2, 
Notch 1 and Notch2 was observed in either GSC11 or X01 (Figure 3C). 
5. The effect of HL156A, TMZ and combination treatment on neuro-glial 
differentiation of GSC11 and X01 TSs 
Either HL156A or TMZ did not promote neuro-glial differentiation as 
the expression of neuronal marker such as olig2, Tuj1, and GFAP were not 
changed (Figure 4). Thus, it is unlikely that the therapeutic effect of HL156A is 
through differentiating tumor cells, which is one of proposed strategies for 
targeting stem cells.    
6. The effect of HL156A, TMZ and combination treatment on the invasive 
property of GSC11 TSs 
 In 3D invasion assay with collagen I matrix, TS treated with HL156A, 
TMZ and combination exhibited less degree of invasiveness than control as 
depicted (Figure 5A, cells with drug treatment at the time of implantation). The 
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effect was most obvious when the combination treatment was given. It was not 
because of drug effects on the cell viability as I also assessed the cell viability 
during the experiment, with no significant cell death. To recapitulate real 
clinical situation where a drug is administered to the patient after the tumor 
formation, I performed the same assay but the treatment of drug was given 12 
hrs after implantation (Figure 5B). Even in this setting, the inhibitory effect of 
invasion was most prominent when the combination treatment was given. As 
several groups reported that EMT related markers were upregulated in GBM 
and the acquisition of mesenchymal traits by cancer cells undergoing EMT has 
been reported to be related with the acquisition of a stem cell program ,19,25 the 
expression of EMT related markers such as β-catenin, zeb1, N-cadherin and 
snail was assessed,  revealing the expression of β-catenin, zeb1, and N-cadherin 
was diminished on the treatment of HL156A and combination treatment,  
suggesting that the agent may perturb the EMT related pathway of the GBM-
TS (Figure 5C).  
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Figure 3. The effect of HL156A, TMZ and combination treatment on 
stemness of GBM-TSs. (A, B) Drug effect on the stemness of GSC11 and X01 
TSs was assessed by the neurosphere formation assay. The number of 
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neurosphere was decreased on the treatment of HL156A and combined 
HL156A and TMZ. (C) The expression of stemness markers, such as CD133 
and Sox, were decreased in the combination treatment group (*: Statistically 
significant). 
 
Figure 4. The effect of HL156A, TMZ and combination treatment on 
neuroglial differentiation of GBM-TSs. The treatment of HL156, TMZ and 
combination of them did not affect neuro-glial differentiation of GSC11 TSs.  
7. Assessment of cellular metabolism by analyzing 18F-FDG uptake  
In order to assess the effect of drugs on the cellular metabolism, 18F-
FDG uptake was examined. The uptake of 18F-FDG was decreased as cells were 
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treated with drugs and the decrease was most prominent when the combination 
treatment was given. Thus, HL156A seems to decrease cellular metabolism and 
the degree of inhibition is most obvious in HL156A and TMZ combination 
treatment (Figure 6).  
8. Gene ontology analysis of microarray data 
Transcriptome analysis by Illumina HumanHT-12 v4 Expression 
BeadChip was acquired and heatmap with hierarchical clustering was generated 
(Figure 7). There are genes differentially expressed when the combination 
treatment was given compared to control group,  among which  several down-
regulated genes such as FBLN7, an adhesion molecule that interacts with 
extracellular matrix, Lyn, a molecule known to regulate cell migration, and 
LAMA4, a laminin were included.  I also analyzes Gene Ontology gene sets for 
differential expression among TMZ and combination treatment using BRB-
Array tool. When compared with TMZ single treatment, the combination 
treatment showed differentially expressed gene sets that include those related 
with cell adhesion, cell migration, cell motion and regulation of cell adhesion 
(Table 1). 
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9. The effect of HL156A on the xenografted tumor growth 
Finally, the effect of drugs on the tumors of orthotopic xenograft mice 
was analyzed. After sacrificing animals, brains of animals were taken out and 
stained. Although combination treatment did not prevent the formation of the 
mass, the size and extent of mass was limited in the combination-treatment 
group mice (Figure 8A).  The survival of the orthotopic xenographfted mice 
(n=5 per group) were analyzed, revealing that the treatment of combination of 
HL156A and TMZ had a benefit in overall survival of animals (p=0.000, log 
rank test, Figure 8B).  
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Figure 5. The effect of HL156A, TMZ and combination treatment on the 
invasive property of GBM-TSs. (A, B) The treatment of HL156A and 
combination of HL156A and TMZ showed decreased invasiveness on 3D 
collagen matrix invasion assay (A: drug treatment at the time of cell 
implantation, B: drug treatment after 12 hrs of cell implantation). (C) Markers 
related with EMT pathway were altered on the treatment of HL156A. 
Expression of β-catenin, zeb1 and N-cadherin was decreased on the treatment 
of HL156A and combination of HL156A and TMZ. 
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Figure 6. F18-FDG uptake was markedly decreased in HL156A, TMZ and 
combination treatment. The decrease in FDG uptake was most prominent in 
combination treatment group, suggestive of low metabolic status (ns : 
statistically not significant). 
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Figure 7. High throughput gene expression microarray. Sets of genes were 
differentially expressed in the combination treatment compared with the control 
and single treatment of either HL156A or temozolmide.  
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Table 1.Results of gene ontology analysis   
  GO category 
GO 
ontology 
GO term 
Number 
of genes 
LS* 
permutation 
p-value 
Efron-
Tibshirani's 
GSA test p-
value 
1 GO:0007155 BP cell adhesion 88 0.00003 0.04 (+) 
2 GO:0022610 BP biological adhesion 88 0.00003 0.04 (+) 
3 GO:0048699 BP generation of neurons 96 0.00008 < 0.005 (-)  
4 GO:0050839 MF 
cell adhesion 
molecule binding 
22 0.00023 0.11 (+) 
5 GO:0001558 BP 
regulation of cell 
growth 
29 0.00023 < 0.005 (+)  
6 GO:0045595 BP 
regulation of cell 
differentiation 
92 0.00029 0.095 (+) 
7 GO:0048870 BP cell motility 93 0.00035 < 0.005 (+)  
8 GO:0051674 BP localization of cell 93 0.00035 < 0.005 (+)  
9 GO:0016477 BP cell migration 92 0.00041 < 0.005 (+)  
10 GO:0034330 BP 
cell junction 
organization 
12 0.00044 < 0.005 (-)  
11 GO:0030182 BP neuron differentiation 86 0.00046 < 0.005 (-)  
12 GO:0000902 BP cell morphogenesis 82 0.00047 0.205 (+) 
13 GO:0016337 BP 
single organismal 
cell-cell adhesion 
28 0.0005 < 0.005 (+)  
14 GO:0009611 BP response to wounding 68 0.0005 0.07 (+) 
15 GO:0016192 BP 
vesicle-mediated 
transport 
73 0.00061 0.335 (+) 
16 GO:0048666 BP neuron development 67 0.00069 < 0.005 (-)  
17 GO:1903035 BP 
negative regulation of 
response to wounding 
9 0.00072 < 0.005 (+)  
18 GO:0005178 MF integrin binding 13 0.00072 < 0.005 (+)  
19 GO:0006897 BP endocytosis 34 0.00074 0.435 (+) 
20 GO:0030155 BP 
regulation of cell 
adhesion 
34 0.00077 < 0.005 (+)  
21 GO:0045216 BP 
cell-cell junction 
organization 
11 0.00077 < 0.005 (-)  
22 GO:0034097 BP response to cytokine 55 0.00078 0.145 (+) 
23 GO:0007160 BP cell-matrix adhesion 12 0.0008 < 0.005 (-)  
24 GO:0031348 BP 
negative regulation of 
defense response 
10 0.00082 < 0.005 (+)  
25 GO:0098602 BP 
single organism cell 
adhesion 
32 0.00096 < 0.005 (+)  
26 GO:0016049 BP cell growth 38 0.00099 < 0.005 (+)  
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27 GO:0030030 BP 
cell projection 
organization 
74 0.001 0.14 (-) 
28 GO:0032102 BP 
negative regulation of 
response to external 
stimulus 
14 0.00101 0.12 (+) 
29 GO:0032989 BP 
cellular component 
morphogenesis 
86 0.00115 0.245 (+) 
30 GO:0034329 BP cell junction assembly 10 0.00117 < 0.005 (-)  
31 GO:0050767 BP 
regulation of 
neurogenesis 
41 0.00133 0.21 (+) 
32 GO:0051093 BP 
negative regulation of 
developmental 
process 
51 0.00159 < 0.005 (+)  
33 GO:0023056 BP 
positive regulation of 
signaling 
76 0.00169 < 0.005 (+)  
34 GO:0010647 BP 
positive regulation of 
cell communication 
77 0.00189 < 0.005 (+)  
35 GO:0031175 BP 
neuron projection 
development 
62 0.00192 0.08 (+) 
36 GO:0001952 BP 
regulation of cell-
matrix adhesion 
5 0.00197 < 0.005 (-)  
37 GO:0031589 BP 
cell-substrate 
adhesion 
19 0.00206 0.03 (-) 
38 GO:0043405 BP 
regulation of MAP 
kinase activity 
18 0.00226 < 0.005 (+)  
39 GO:0050728 BP 
negative regulation of 
inflammatory 
response 
7 0.00245 < 0.005 (+)  
40 GO:2001237 BP 
negative regulation of 
extrinsic apoptotic 
signaling pathway 
9 0.00251 < 0.005 (+)  
41 GO:0000904 BP 
cell morphogenesis 
involved in 
differentiation 
64 0.00253 0.08 (+) 
42 GO:0043588 BP skin development 24 0.0026 0.25 (+) 
43 GO:0007264 BP 
small GTPase 
mediated signal 
transduction 
23 0.00263 0.21 (-) 
44 GO:0009897 CC 
external side of 
plasma membrane 
17 0.00271 0.055 (+) 
45 GO:0051216 BP cartilage development 13 0.00324 < 0.005 (+)  
46 GO:0045664 BP 
regulation of neuron 
differentiation 
33 0.00344 0.21 (+) 
47 GO:0007266 BP 
Rho protein signal 
transduction 
7 0.00345 < 0.005 (-)  
48 GO:0043406 BP 
positive regulation of 
MAP kinase activity 
11 0.00348 < 0.005 (-)  
49 GO:0051960 BP 
regulation of nervous 
system development 
44 0.00351 < 0.005 (+)  
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50 GO:0061448 BP 
connective tissue 
development 
17 0.00353 < 0.005 (+)  
51 GO:0033559 BP 
unsaturated fatty acid 
metabolic process 
6 0.00368 < 0.005 (+)  
52 GO:1903034 BP 
regulation of response 
to wounding 
31 0.00371 0.145 (+) 
53 GO:0006909 BP phagocytosis 11 0.00395 0.34 (+) 
54 GO:0048864 BP stem cell development 16 0.00416 < 0.005 (+)  
55 GO:0061024 BP 
membrane 
organization 
44 0.00425 0.035 (+) 
56 GO:0006954 BP 
inflammatory 
response 
34 0.00427 0.145 (+) 
57 GO:0030054 CC cell junction 80 0.00438 0.175 (-) 
58 GO:0030098 BP 
lymphocyte 
differentiation 
13 0.00448 0.4 (+) 
59 GO:0048771 BP tissue remodeling 18 0.00453 0.15 (-) 
60 GO:0022407 BP 
regulation of cell-cell 
adhesion 
13 0.00458 < 0.005 (+)  
61 GO:0032990 BP 
cell part 
morphogenesis 
59 0.00479 0.14 (-) 
 
Differentially expressed gene sets between TMZ and combination treatment. 
Expression of several gene sets related cellular adhesion and migration (bold 
highlight) was significantly different between two groups (* LS : least square).  
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Figure 8.  The effect of HL156A and combined HL156A and TMZ on the 
xenografted tumor growth and survival of animal. (A) Tumors from 
HL156A, TMZ, and combined HL156A and TMZ treated animals were stained 
and examined. HL156A and combination treated animal showed less irregular 
margin than that of control. Especially, combination treatment group showed 
tumors with decreased volume. (B) Survival of the combination treatment 
group was significantly increased (p=0.0000). 
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IV. DISCUSSION  
In spite of recent progress in the understanding of GBM, survival of 
patients is still very limited. Even after a complete resection was achieved at 
the time of operation, it tends to recur and takes patient’s life. A new strategy 
against the disease is required, accordingly. Targeting GBM-TS and 
identification of key molecules related with the unique properties may be a 
reasonable approach as many reports showed chemo- and radio-resistance of 
GBM-TS that potentially cause recur of the disease.  
In the present study, I examined the effect of HL156A, TMZ and 
combination treatment on the stemness and invasive property of GBM-TS. The 
combination treatment of new agent HL156A and conventional TMZ, inhibited 
stemness and invasive properties of GSC11, and this effect seemed to be related 
with the alteration of EMT related markers. Similar additive effect of metformin 
with conventional therapy was found on the breast cancer stem cells model.34 
This group showed an additive effect of metformin in the cytotoxic effect of 
hyperthermia and this was via the activation of AMPK and inactivation of 
mTOR.34 Furthermore, it was shown that metform killed and radiosensitized 
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cancer cells and preferentially killed cancer stem cells of breast.35 This kind of 
effect was also known in GBM. One group reported metformin plus TMZ-base 
chemotherapy as an adjuvant treatment for WHO grade III and IV malignant 
gliomas.36 And another group specifically target cancer stem cells of GBM by 
metformin plus sorafenib.37 The possible explanation of the superior result of 
survival in the combination treatment group in this study may be contributed to 
1) the tumor cytotoxic effect of TMZ in addition to the deteriorated cellular 
energy metabolism environment induced by HL156A 2) the additive inhibitory 
effect of TMZ and HL156A on the invasive property of  TSs, which results in 
the less aggressive tumor phenotype. Given the heterogeneity of cancer cells, 
targeting GBM-TSs by general metabolic stress seems to be a reasonable 
approach as it may provide less favorable environment to the metabolically 
active tumor cells generally. Although a well-known biguanide metformin may 
have similar effect as HL156A, the delivery of metformin to the brain is limited. 
The new compound overcomes this shortcoming and generally shows high 
bioavailability. Further study on this combination treatment strategy with this 
new compound in addition to the conventional therapy in the treatment of 
malignant tumor need to be performed.  
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The cellular mechanism underlying the effect of HL156A seems 
distinctive in that it did not show expected AMPK activation and consequent 
mTOR inhibition pathway in the setting of GBM, as in this study. Recently, Liu 
et al. reported that AMPK is activated in the glioblastoma and the anti-
proliferative effect of metformin is AMPK independent. Degrading cdc25 
through proteasome and/or increasing PRAS40-RAPTOR interaction were 
suggested as inhibitory effectors for mTOR, independent of AMPK in this 
study.38 The present study also confirmed increased basal AMPK expression in 
GSC11 and X01 TSs and similarly, AMPK activation and consequent mTOR 
inhibition was not obvious in the inhibitory effect of HL156A and combination 
treatment on the GBM-TSs. It was not possible to verify these phenomena in 
the gene expression microarray data as most of genes were filtered out during 
the quality-controlprocess. Interestingly, expression of DNA-Damage-
Inducible Transcript 4 (DDIT4), having inhibitory effect on mTOR1, was 
significantly increased in combination treatment group. Elucidation of this 
increase with regards to TS- inhibitory effect of combination treatment need to 
be sought, as growth inhibitory effect of HL156A was not obvious in the tested 
concentration. Although it was not obvious in the concentration up to 200μM, 
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it is still worth assessing effect of drugs on GBM-TS in higher dose range with 
regards to the activation of AMPK and subsequent mTOR inhibition. In 
addition, the direct experimental assessment of OXPHOS pathway in GBM-TS 
in the setting of inhibitory effect of drugs need to be performed for the further 
study.  
Another unique aspect of the result of this work is that the inhibitory 
effect on the invasive property of GBM-TSs may be related with the alteration 
of EMT related markers. The evidence of EMT pathway in the pathogenesis of 
GBM expansion and invasion is not robust at this point. Even though there 
exists a similarity in the process of GBM invasion and immature neuron 
migration during embryonic development, little is known in the process and 
direct evidence of relation of invasive property and EMT is still lacking. 
Nevertheless, several evidence suggested similar molecular alteration happen 
to be exist in the GBM pathophysiology and outcome after inhibiting this 
pathway need to be studied to identify the role of this pathway in the invasive 
property of this fatal disease. Similar experiment with targeting EMT pathway 
by siRNA or shRNA may help.   
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Even after identifying TMZ responsive group, the patients succumb to 
death by relapse of the disease. There were several strategies proposed for 
overcoming therapeutic limitation of GBMs, most of them still not successful. 
Due to the intrinsic infiltrative nature of the tumor into the normal brain tissue, 
the complete resection during the operation seems impossible. Thus, proper 
adjuvant therapy for the potential remaining cancer cells including cancer stem 
cells seems crucial to overcome the detrimental fate of the disease. Targeting of 
GBM-TSs as a new strategy need to be extensively evaluated in this context. 
Caveats of the theory is limited information regarding the identification of 
GBM specific stem cells, which makes sorting out the cells for the experiment 
limited. For example, there still are controversies on the surface markers that 
defined cancer stem cells. Furthermore, some properties of GBM is able to be 
explained by the clonal evolution model of the disease, another axis of tumor 
heterogeneity. Heterogeneity defined by spatial structure of tumor can be 
explained better by the clonal evolution model. As combined model also was 
suggested, more evidence need to be accumulated to understand this specific 
nature of the disease. General intracellular energy metabolism alteration seems 
to be a reasonable therapeutic approach as it is able to target neoplastic cells  by 
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this strategy in both models. Accordingly, usage of this newly developed agent 
HL156A combined with conventional TMZ for the targeting GBM-TSs, need 
to be further evaluated as a new strategy against the disease.   
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V. CONCLUSION  
I assessed an effect of a newly developed biguanide, HL156A on the 
properties of GBM-TSs and survival of orthotopic xenograft animals, to assess 
the feasibility of this newly developed agent for the treatment of GBM, alone 
or combined with conventional therapeutic agent TMZ. HL156A, especially 
combined with TMZ exhibited inhibitory effect on the stemness of GBM-TSs, 
proven by sphere formation assay and the assessment of marker expression, 
without affecting viability of cells. Secondly, HL156A did not promote neuro-
glial differentiation. Thirdly, the invasive properties of GBM-TSs were 
inhibited by the combination treatment, compared with the control and TMZ 
alone treated groups in 3-dimentional collagen matrix invasion assay. Fourthly, 
treatment of combined HL156A and TMA seems to repress epithelial-
mesenchymal transition (EMT) related gene expression. Fifthly, gene ontology 
class comparison of TMZ and combination treatment group reveals altered 
expression of gene sets involving cellular adhesion and migration. Finally, the 
combined treatment of HL156A and TMZ showed survival benefits in the 
orthotopic xenograft mouse model. In conclusion, targeting of GBM-TSs by 
the combination of HL156A and TMZ, through the inhibition of stemness and 
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invasion properties of GBM- TSs, can be a novel candidate for the treatment of 
GBM. 
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ABSTRACT (IN KOREAN) 
새롭게 개발된 바이구아나이드 화합물에 의한  
교종 종양구 억제 효과   
 
<지도교수 김 세 훈> 
 
연세대학교 대학원 의과학과  
최 준 정 
 
 
 교모세포종(glioblastoma)은 치명적인 중추신경계의 병으로, 
최근 이 분야의 연구의 발전에도 불구하고 제한적인 생존율을 보이고 
있으며, 따라서 새로운 치료전략의 수립이 필요한 병이다.최근 
악성종양의 치료제로 바이구아나이드(biguanide)의 역할이 대두되어 
연구되어 있으며, 일부에서 바이구아나이드의 종양구에 대한 효과가 
보고되고 있다. 본 연구에서 새롭게 개발된 바이구아나이드 화합물 
HL156 의 교모세포종의 치료제로서의 적합성을 판정하기 위하여, 
HL156A 단독, 그리고 기존치료제 테모졸로마이드와의 병합 시 
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동소이종이식 마우스에서의 생존율을 평가하였다.  HL156A 와 
테모졸로마이드와의 병합투여의 교모세포종 종양구의 줄기세포능 
저하영향을 종양구 형성실험과 마커 발현을 통해 확인하였으며, 
삼차원 콜라겐 기질 침윤분석을 통하여 병합투여가 교모세포종 
종양구의 침윤성을 억제하는 것을 확인하였다.  또한, HL156A의 단독, 
혹은 병합투여는 상피-간질이행 관련 유전자 발현을 억제하는 효과를 
나타내었다. 유전자 온톨로지 분석을 통하여, 병합투여시 
테모졸로마이드 단독투여 때보다 세포 접착 및 세포 이동과 관련한 
유전자세트의 변화가 있음을 확인하였다. 마지막으로, HL156A 의 
테모졸로마이드와의 병합투여는 동소 이종 이식마우스 모델에서 
생존의 유의한 생존 증가를 나타내었다. 결론적으로, 개발된 
바이구아나이드 화합물은 교모세포종 종양구의 줄기세포능과 
침윤성을 억제하여 교모세포종의 새로운 치료제로 사용될 수 있으며 
이에 대한 평가가 추후로 이루어져야 한다.  
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